

Subcommittee Name: Gynecological Subcommittee

Co-chairs

| Name              | Country | Term started | Term ends* |
|-------------------|---------|--------------|------------|
| Lilie Lin         | USA     | 2024         |            |
| Tatsuya Ohno      | Japan   | 2024         |            |
| Amelia Barcellini | Italy   | 2026         |            |

\* The term of office is 3 years and may be renewed once, for a maximum total service of 6 years. It is recommended that the 3 co-chairs come from 3 different continents (America, Asia, Europe). To ensure continuity, it is recommended that the co-chairs step down on a staggered basis following their first three-year term.

**Subcommittee Achievements (e.g. white papers, publications, workshops, ...) – max 2,000 characters including spaces**

- **Paper accepted and published**

- 1) Barcellini A, Lin LL, Durante M, Ohno T. Letter to the Editor: Modern Management of Newly Diagnosed Vulvovaginal Melanoma: Is There a Role for Carbon Ion Radiotherapy? A Perspective From the Particle Therapy Co-Operative Group (PTCOG) Gynecological Subcommittee. *J Natl Compr Canc Netw*. 2026;24(7):e267053. doi:10.6004/jnccn.2026.7053

The letter was submitted in response to the recently published article by Leita MM Jr (doi:10.6004/jnccn.2025.7081). In this review, the author discussed emerging therapeutic strategies for vulvovaginal melanoma, including hypofractionated photon radiotherapy without mentioned carbon ion radiotherapy. In light of the currently available preclinical and clinical evidence supporting the use of carbon ion radiotherapy in this setting, we emphasized that carbon ion therapy should be considered a promising treatment option for these rare and intrinsically radioresistant histological subtypes.

- 2) Barcellini A, Contreras JA, Krause KJ, et al. Particle Beam Radiotherapy for Gynecologic Cancers: A Scoping Review and Expert Opinion by the Particle Therapy Cooperative Group - Gynecologic Subcommittee. *Int J Radiat Oncol Biol Phys*. Published online August 14, 2026. doi:10.1016/j.ijrobp.2026.08.005

The review was performed in accordance with the PRISMA-ScR guidelines, and the risk of bias was assessed using the JBI critical appraisal tools. A total of 414 unique records were identified, of which 41 studies met the eligibility criteria and were included in the final analysis. The included publications spanned the period from 1976 to 2025, with 63.4% published between 2018 and 2025. Most studies originated from Japanese particle therapy centers (63.4%). Carbon ion radiotherapy was the most frequently investigated modality, predominantly used for the radical treatment of radioresistant gynecological malignancies, including melanoma and locally advanced cervical cancer. Proton beam radiotherapy was primarily employed in the postoperative and recurrent disease settings. The findings of this work were presented as an oral presentation at the most recent PTCOG Annual Meeting.

**Do you maintain a mailing list of subcommittee members (Yes/No)? Yes**

**Should the subcommittee continue its work (Yes/No)? Yes**

**If yes, please describe the planned activities and goals for the next 3 years – max 2,000 characters including spaces**

- **International Practice Patterns and Trends in the Utilization of Particle Therapy for Gynecologic Malignancies: Clinical and Physics Assessment**

A multinational PTCOG survey entitled "*International Practice Patterns and Trends in the Utilization of Particle Therapy for Gynecologic Malignancies: Clinical and Physics Assessment*" has been developed and will be distributed to all PTCOG members. This cross-sectional observational study targets radiation oncologists and medical physicists practicing at proton and carbon ion therapy centers worldwide. Institutional Review Board (IRB) approval has been obtained, and the survey will be administered through REDCap. The primary objective is to characterize current institutional practices in treatment planning, delivery techniques, and dose optimization for particle therapy in gynecologic malignancies. Secondary objectives include evaluating inter-institutional variability, identifying opportunities for standardization and collaboration, and establishing a benchmark dataset to support future PTCOG consensus statements and clinical trial development. Survey distribution will begin in June 2026, with a 3-month data collection period and scheduled reminder emails. Data analysis is planned for September 2026, with initial results to be submitted as a conference abstract and manuscript submission anticipated in the first quarter of 2027.

- **Consensus paper**

The PTCOG Gynecologic Subcommittee is developing a consensus manuscript entitled "*Clinical Implementation of Particle Therapy for the Treatment of Gynecological Tumors: Technical Recommendations and Best Practices from the PTCOG Gynecologic*

*Subcommittee.*" The document will provide evidence-based recommendations and best practices for the clinical implementation of proton and carbon ion therapy, covering key aspects including patient selection, imaging and simulation, target delineation, treatment planning and robust optimization, image guidance, and treatment monitoring. Manuscript submission is planned for Q4 2026.

- **Discussion of new collaborative research projects during the Subcommittee session at the latest PTCOG meeting.**
  - Preparation of a white paper on the role of particle therapy in the management of gynecological melanomas.
  - Retrospective multicentric evaluation and preparation of a white paper on particle therapy for the re-irradiation of gynecological malignancies.
  - Retrospective multicentric evaluation of clinical outcomes in patients with gynecological adenoid cystic carcinomas treated with particle therapy
  - Retrospective evaluation of the clinical outcomes and treatment-related toxicity of particle therapy in patients with oligorecurrent/oligometastatic ovarian cancer

Please circulate this form to all subcommittee members and once agreed upon by the subcommittee submit it to: [secretariat@ptcog.online](mailto:secretariat@ptcog.online) (cc: [m.durante@gsi.de](mailto:m.durante@gsi.de)) within:

**August 30, 2026**

Please attach the list of subcommittee members (name and country).

The information contained in this form and the list of members will be uploaded on the webpage of your subcommittee (see: <https://ptcog.online/subcommittee/>).

| Name         | Surname          | Country     |
|--------------|------------------|-------------|
| Amelia       | Barcellini       | Italy       |
| Lilie L      | Lin              | USA         |
| Tatsuya      | Ohno             | Japan       |
| Charles      | Simone           | USA         |
| Huan         | Giap             | USA         |
| Alexandra    | Charalampopoulou | Italy       |
| Tien Yee Amy | Chang            | Hong Kong   |
| Neil         | Taunk            | USA         |
| Alessandro   | Vai              | Italy       |
| Allison      | Garda            | USA         |
| Won Kyung    | Cho              | South Korea |
| Fantine      | Giap             | USA         |
| Yuting       | Li               | USA         |
| Richard      | Amos             | UK          |
| Chris        | Weil             | USA         |
| Arians       | Nathalie         | Germany     |
| Jessica      | Jutzy            | USA         |
| Zuofeng      | Li               | USA         |
| Asma         | Sarwar           | UK          |
| Isabelle     | Choi             | USA         |
| Jeremy       | Godart           | Netherlands |
| Keyur        | Mehta            | USA         |
|              |                  |             |